Publication: How bio-questionable are the different recombinant human erythropoietin copy products in Thailand?
Issued Date
2014-01-01
Resource Type
ISSN
1573904X
07248741
07248741
Other identifier(s)
2-s2.0-84902267321
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Pharmaceutical Research. Vol.31, No.5 (2014), 1210-1218
Suggested Citation
Liem Andhyk Halim, Vera Brinks, Wim Jiskoot, Stefan Romeijn, Kearkiat Praditpornsilpa, Anunchai Assawamakin, Huub Schellekens How bio-questionable are the different recombinant human erythropoietin copy products in Thailand?. Pharmaceutical Research. Vol.31, No.5 (2014), 1210-1218. doi:10.1007/s11095-013-1243-9 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/33495
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
How bio-questionable are the different recombinant human erythropoietin copy products in Thailand?
Abstract
Purpose: The high prevalence of pure red cell aplasia in Thailand has been associated with the sharp increase in number of recombinant human erythropoietin (rhEPO) copy products, based on a classical generic regulatory pathway, which have entered the market. This study aims to assess the quality of rhEPO copy products being used in Thailand. Methods: Twelve rhEPO copy products were purchased from pharmacies in Thailand, shipped under controlled cold chain conditions to the Netherlands and characterized using (1) high performance size-exclusion chromatography, (2) asymmetrical flow field-flow fractionation, (3) sodium dodecyl sulfate polyacrylamide gel electrophoresis in combination with (4) Western blotting and additionally tested for (5) host cell protein impurities as well as (6) endotoxin contamination. Results: Some of the tested rhEPO copy products showed high aggregate levels and contained a substantial amount of protein fragments. Also, one of rhEPO copy products had a high endotoxin level, exceeding the FDA limit. Conclusions: Our observations show that some of the tested copy products on the Thai market differ significantly from the originator rhEPO product, Epogen®. This comparison study supports a link between the quality attributes of copy rhEPO products and their immunogenicity. © 2013 Springer Science+Business Media New York.